Population pharmacokinetic analysis of denosumab in Patients with Bone Metastases from Solid Tumours

Clinical Pharmacokinetics

Volumn 51, Issue 4, 2012, Pages 247-260

  Gibiansky, Leonid ^a   Sutjandra, Liviawati ^b   Doshi, Sameer ^b   Zheng, Jenny ^b   Sohn, Winnie ^b   Peterson, Mark C ^b   Jang, Graham R ^b   Chow, Andrew T ^b   Pérez Ruixo, Juan José ^b  

^a QuantPharm LLC 49 Flints Grove Drive   (United States)

^b AMGEN INC   (United States)

Author keywords

Denosumab; Modelling; Nonlinear Dynamics; Pharmacokinetics; Pharmacology; Population pharmacokinetics; RANK ligand inhibitors.

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR;

ARTICLE; BONE METASTASIS; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SOLID TUMOR;

ANTIBODIES, MONOCLONAL; BIOLOGICAL AVAILABILITY; BONE NEOPLASMS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; MALE; MODELS, BIOLOGICAL; NEOPLASMS; RANK LIGAND; TISSUE DISTRIBUTION;

EID: 84858251410     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11598090-000000000-00000     Document Type: Article

References (47)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-9s
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-94
3. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-76
4. Abrahm JL, Banffy MB, Harris MB. Spinal cord compression in patients with advanced metastatic cancer: "all I care about is walking and living my life". JAMA 2008; 299: 937-46
5. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-9
6. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145: 527-38
7. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76
8. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-602
9. Elliott R, Kostenuik PJ, Chen C, et al. Denosumab is a selective inhibitor of human receptor activator of NF-KB ligand (RANKL) that blocks osteoclast formation and function [abstract no. P149]. Osteoporos Int 2007; 18: S54
10. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19
11. Akatsu T, Murakami T, Nishikawa M, et al. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 1998; 250: 229-34
12. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564-71
13. Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14: 6690-6
14. Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006; 12: 1221-8
15. Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci 2008; 99: 1237-42
16. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010; 28: 5132-9
17. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-32
18. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011; 377: 813-22
19. Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetics meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 2011; 50: 793-807
20. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059-66
21. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giantcell tumour of bone: An open-label, phase 2 study. Lancet Oncol 2010; 11: 275-80
22. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001; 28: 507-32
23. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NFkappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000; 275: 768-75
24. Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 2005; 22: 1589-96
25. Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the targetmediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 2008; 35: 573-91
26. Ma P. Theoretical considerations of target-mediated drug disposition models: Simplifications and approximations. Pharm Res 2012; 29: 866-82
27. Girard P. Data transformation and parameter transformations inNONMEM. Eleventh Meeting, Population Approach Group in Europe; 2002 Jun 6-7; Paris [online]. Available from URL: Http://www.page-meeting.org/page/page2002/ PascalGirardPage2002.pdf [Accessed 2012 Feb 15]
28. Mahmood I. Clinical pharmacology of therapeutic proteins. Rockville (MD): Pine House Publishers, 2006
29. Kuester K, Kloft C. Pharmacokinetics of monoclonal antibodies. In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs: Principles and case studies in drug development. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2006: 45-91
30. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-58
31. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-68
32. Block G, Bone HG, Fang L, et al. A single dose study of denosumab in patients with various degrees of renal impairment [abstract no. 57]. J Amer Kidney Dis 2010; 55 (4): B46
33. Gastonguay MR. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: A review of methodology and 42 case studies.Twentieth Meeting, Population Approach Group in Europe; 2011 Jun 7-10; Athens [online]. Available from URL: Http://www.page-meeting.org/pdf-assets/1694-GastonguayPAGE2011.pdf [Accessed 2012 Feb 16]
34. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92
35. Pérez-Ruixo JJ, Piotrovskij V, Zhang S, et al. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Br J Clin Pharmacol 2006; 62: 81-96
36. Frame B, Koup J, Miller R, et al. Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections: Experience with heterogeneous pharmacokinetic data. Clin Pharmacokinet 2001; 40: 307-15
37. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 633-59
38. Olsson-Gisleskog P, Jacqmin P, Pérez-Ruixo JJ. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinet 2007; 46: 159-73
39. Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today 2007; 12: 1018-24
40. Roskos LK, Davis CG, SchwabGM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 2004; 61: 108-20
41. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009; 24: 182-95
42. Hofbauer LC, Schoppet M, Schuller P, et al. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol (Oxf) 2004; 60: 214-9
43. Liu JM, Zhao HY, Ning G, et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75. Calcif Tissue Int 2005; 76: 1-6
44. Findlay D, Chehade M, Tsangari H, et al. Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther 2008; 10: R2 [online]. Available from URL: Http://arthritisresearch. com/content/pdf/ar2348.pdf [Accessed 2011 Oct 6]
45. Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther 2008; 326: 555-62
46. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-35
47. Hayashi N, Tsukamoto Y, Sallas WM, et al. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63: 548-61